Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285682041> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W4285682041 endingPage "193" @default.
- W4285682041 startingPage "183" @default.
- W4285682041 abstract "There is emerging evidence for the use of poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with mCRPC with patients harboring germline or somatic mutations deriving clinical benefit. However, the toxicity profile of PARPi in mCRPC is not well established. In March 2022 a literature search was conducted across 4 databases - Medline, PubMed, Cochrane Library and Embase. In total, 14 relevant studies were identified cumulating in 2066 patients that were treated with PARPi. The overall ORR to PARPi alone or in combination with other therapy was 37% (246/666). In 5trials that investigated PARPi alone, the ORR was 39% (141/361). Treatment emergent adverse events (TEAEs) of any grade were reported in 96% (1034/1080) in PARPi treatment arms. TEAEs of grade >= 3 were reported in 57% (611/1080). 45% (457/1006) experienced treatment interruption whilst 31% (310/989) required dose reductions. 11% (114/1006) of patients had their treatment discontinued directly as the result of toxicity associated with the trial medications. The most common hematological toxicity was anemia, reported in 490/1160 (42%) patients. and lowered white blood cell count were the next 2most common toxicities, reported in 186/655 (28%) and 133/729 (18%) respectively. The 3most common non-hematological toxicities reported were nausea, fatigue and anorexia reported in 440/1013 (43%), 340/1013 (34%) and 274/1013 (27%) patients respectively. Overall, TRAEs associated with individual PARPi are still emerging with hematological toxicities being most apparent. Further toxicities will be informed from future clinical trials to allow improved treatment selection, education and management of toxicities in prostate cancer." @default.
- W4285682041 created "2022-07-17" @default.
- W4285682041 creator A5016755297 @default.
- W4285682041 creator A5046610488 @default.
- W4285682041 creator A5053221582 @default.
- W4285682041 creator A5071226647 @default.
- W4285682041 creator A5071552439 @default.
- W4285682041 date "2023-02-01" @default.
- W4285682041 modified "2023-10-16" @default.
- W4285682041 title "Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer" @default.
- W4285682041 cites W2037352738 @default.
- W4285682041 cites W2156978580 @default.
- W4285682041 cites W2235405584 @default.
- W4285682041 cites W2340422569 @default.
- W4285682041 cites W2462985846 @default.
- W4285682041 cites W2597062310 @default.
- W4285682041 cites W2779062531 @default.
- W4285682041 cites W2806421431 @default.
- W4285682041 cites W2884001607 @default.
- W4285682041 cites W2902703786 @default.
- W4285682041 cites W2975141952 @default.
- W4285682041 cites W2979282490 @default.
- W4285682041 cites W2989894179 @default.
- W4285682041 cites W3006844234 @default.
- W4285682041 cites W3008060424 @default.
- W4285682041 cites W3015368557 @default.
- W4285682041 cites W3020771563 @default.
- W4285682041 cites W3023296125 @default.
- W4285682041 cites W3027745881 @default.
- W4285682041 cites W3033636278 @default.
- W4285682041 cites W3049351332 @default.
- W4285682041 cites W3049409207 @default.
- W4285682041 cites W3083429069 @default.
- W4285682041 cites W3084418387 @default.
- W4285682041 cites W3119595811 @default.
- W4285682041 cites W3137618571 @default.
- W4285682041 cites W3190141894 @default.
- W4285682041 cites W4212780237 @default.
- W4285682041 cites W4212977599 @default.
- W4285682041 cites W4226401827 @default.
- W4285682041 doi "https://doi.org/10.1016/j.clgc.2022.07.005" @default.
- W4285682041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35927195" @default.
- W4285682041 hasPublicationYear "2023" @default.
- W4285682041 type Work @default.
- W4285682041 citedByCount "2" @default.
- W4285682041 countsByYear W42856820412023 @default.
- W4285682041 crossrefType "journal-article" @default.
- W4285682041 hasAuthorship W4285682041A5016755297 @default.
- W4285682041 hasAuthorship W4285682041A5046610488 @default.
- W4285682041 hasAuthorship W4285682041A5053221582 @default.
- W4285682041 hasAuthorship W4285682041A5071226647 @default.
- W4285682041 hasAuthorship W4285682041A5071552439 @default.
- W4285682041 hasConcept C121608353 @default.
- W4285682041 hasConcept C126322002 @default.
- W4285682041 hasConcept C143998085 @default.
- W4285682041 hasConcept C197934379 @default.
- W4285682041 hasConcept C2776478404 @default.
- W4285682041 hasConcept C2778248108 @default.
- W4285682041 hasConcept C2780192828 @default.
- W4285682041 hasConcept C2780580376 @default.
- W4285682041 hasConcept C29730261 @default.
- W4285682041 hasConcept C535046627 @default.
- W4285682041 hasConcept C71924100 @default.
- W4285682041 hasConcept C95190672 @default.
- W4285682041 hasConceptScore W4285682041C121608353 @default.
- W4285682041 hasConceptScore W4285682041C126322002 @default.
- W4285682041 hasConceptScore W4285682041C143998085 @default.
- W4285682041 hasConceptScore W4285682041C197934379 @default.
- W4285682041 hasConceptScore W4285682041C2776478404 @default.
- W4285682041 hasConceptScore W4285682041C2778248108 @default.
- W4285682041 hasConceptScore W4285682041C2780192828 @default.
- W4285682041 hasConceptScore W4285682041C2780580376 @default.
- W4285682041 hasConceptScore W4285682041C29730261 @default.
- W4285682041 hasConceptScore W4285682041C535046627 @default.
- W4285682041 hasConceptScore W4285682041C71924100 @default.
- W4285682041 hasConceptScore W4285682041C95190672 @default.
- W4285682041 hasIssue "1" @default.
- W4285682041 hasLocation W42856820411 @default.
- W4285682041 hasLocation W42856820412 @default.
- W4285682041 hasOpenAccess W4285682041 @default.
- W4285682041 hasPrimaryLocation W42856820411 @default.
- W4285682041 hasRelatedWork W1980872763 @default.
- W4285682041 hasRelatedWork W2057659215 @default.
- W4285682041 hasRelatedWork W2363890076 @default.
- W4285682041 hasRelatedWork W2380979459 @default.
- W4285682041 hasRelatedWork W2384102814 @default.
- W4285682041 hasRelatedWork W2888625382 @default.
- W4285682041 hasRelatedWork W2956249214 @default.
- W4285682041 hasRelatedWork W2962601203 @default.
- W4285682041 hasRelatedWork W3137663875 @default.
- W4285682041 hasRelatedWork W4317233611 @default.
- W4285682041 hasVolume "21" @default.
- W4285682041 isParatext "false" @default.
- W4285682041 isRetracted "false" @default.
- W4285682041 workType "article" @default.